SpinalCyte announces final human dermal fibroblast transplantation phase two results


SpinalCyte has announced the final results of its phase two animal studies for transplantation of human dermal fibroblasts (HDFs) for intervertebral disc degeneration.

Previously reported was a significant improvement in disc height. This final report builds on those findings with optimal dosage, biochemistry and biomechanics. The study began in 2014 with Rush University and Howard An, the Morton International Endowed chair professor of Orthopedic Surgery, director, Division of Spine Surgery and Spine Fellowship Program, Rush University Medical Center (Chicago, USA).

When injected with HDFs, the discs were able to significantly increase regeneration, disc height, gene expression of structural genes such as collagen type one and collagen type two, and the contents of structural proteins such as proteoglycan. The study has also shown the spinal disc to be immune privileged. “These results suggest HDFs are a promising option for cell therapy which can restore structure, height and reduce symptoms of degenerated discs,” states Howard An.